Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.480 -0.160 (-2.09%)
Official Closing Price Updated: 8:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
40 41 Next >
Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic
Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023: 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2024 Financial Results, Business Highlights
Via Investor Brand Network
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Cybin Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M
Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering
Via Investor Brand Network
Cybin Announces Closing of Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort
Via Investor Brand Network
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Overnight Public Offering
Via Investor Brand Network
US Stocks Mixed; Pfizer Earnings Beat Views
U.S. stocks were mixed this morning, with the Dow Jones trading slightly higher on Tuesday. Following the market opening Tuesday, the Dow traded up 0.03% to 35,568.68 while the NASDAQ fell 0.57% to... 
Via Benzinga
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Why TETRA Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Gainers American Superconductor Corporation (NASDAQ: AMSC) shares surged 112.1% to $21.38 in pre-market trading. AMSC is expected to report first-quarter results on Aug. 9, 2023. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for a look at the biggest pre-market stock movers as we check out the latest news worth reading on Tuesday morning! 
Via InvestorPlace
Cybin Announces Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference
Via Investor Brand Network
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Global CRO Partner to Study, Develop CYB003 as Effective MDD Treatment
Via Investor Brand Network
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
Cybin One Steps Away From Complete Dosing 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Significant Milestone in Advancing CYB003 Towards Pivotal Studies
Via Investor Brand Network
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use
A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance. 
Via Benzinga
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Via Investor Brand Network
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.